translation agency

Genetics Institute suspends phase II study of rhiL-12. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 2714.

June 30, 1996
J Int Assoc Physicians AIDS Care. 1995 Jun;1(5):34. Unique Identifier :

Genetics Institute, Inc. has suspended its phase II clinical trial of recombinant human interleukin-12 (rhIL-12) to treat patients with advanced kidney cancer since several patients required hospitalization (one died), following administration of the drug. The company is investigating to determine if the drug caused these events. It is suspected that the adverse effects may be related to the change in dosing schedule or dosage form. This hypothesis is currently being tested.

Clinical Trials, Phase II Human Interleukin-12/ADVERSE EFFECTS/*THERAPEUTIC USE Kidney Neoplasms/*THERAPY Recombinant Proteins/ADVERSE EFFECTS/THERAPEUTIC USE Treatment Outcome NEWSLETTER ARTICLE